Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
          Clinical Improvement
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Clinical Improvement

Ventavis® (iloprost) Inhalation Solution is the first PAH therapy in which clinical improvement was the primary endpoint of study design. In a placebo-controlled, randomized, double-blind, multicenter study, patients in the Ventavis group saw a nearly 5-fold improvement in clinical endpoint versus patients in the placebo.1

Primary endpoint of study

See if patients on Ventavis showed significant clinical improvement after 12 weeks of therapy compared to patients taking placebo.

The primary endpoint was a combined measure of 3 factors1:

  1. Lack of clinical deterioration or death
  2. Improved walking distance on the 6-minute walk test by at least 10%
  3. Improvement in one (1) NYHA functional class

Significant improvement in composite clinical endpoint1

AIR Pivotal Trial Randomized, double-blind, multicenter, placebo-controlled trial to evaluate the efficacy and safety of Ventavis in the treatment of PAH NYHA Class III or IV (n=146).
* Composite clinical endpoint defined as a) at least 10% increase vs. baseline in 6-minute walk distance with b) improvement by at least one NYHA Class vs. baseline without c) death or clinical worsening
† WHO Group I includes idiopathic PAH, familial PAH, PAH associated with related condition (e.g., collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, HIV infection, drugs and toxins, etc.)
‡ Change from baseline to 12 weeks with measurement 30 minutes after dosing.

1. Ventavis (iloprost) Full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2010.
2. Olschewski H, Simonneau G, Galie N et al, for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.



* In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

IMPORTANT SAFETY INFORMATION:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Please see full Prescribing Information

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).

Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

ACTELION